用于治疗性结肠炎的素载和贝复合纳米颗粒
Xiaoyan Mu1, Hemin Roghzai2, Lingwen Zeng3
1School of Pharmacy, Changzhou University, Changzhou 213164 China; School of Chemical Engineering, Changzhou University, Changzhou 213164 China.
概括
微流体技术有效地创造了含有黄素的+糖混合纳米粒子. 这些纳米颗粒有望提高黄素的生物可用性和治疗肠炎,包括性结肠炎.
科学领域:
- 食品科学与技术 食品科学与技术
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
背景情况:
- 黄素 (Cur) 具有强大的抗氧化和抗炎性质,但其生物利用性较差.
- 开发有效的输送系统对于利用Cur的治疗潜力至关重要,特别是在食品应用和治疗炎症疾病中.
研究的目的:
- 使用微流体技术开发和表征素加载的Zeen+贝 (Z+S) 混合纳米粒子 (NP).
- 评估这些NP的物理化学性质,稳定性,生物相容性和治疗疗效,用于食品应用和肠炎治疗.
主要方法:
- 利用微流体技术制造Z+S混合NP封装黄素.
- 研究了糖比例和黄度对颗粒大小,多散指数 (PDI) 和封装效率 (EE) 的影响.
- 通过Zeta潜力评估结合体稳定性,与正常细胞的生物相容性,自由基清除活性,以及在硫酸诱导肠炎模型中的体内疗效.
主要成果:
- 微流体能够形成稳定的Z+S混合NP,具有可调节的粒子大小和PDI.
- 增加的糖比例降低了颗粒大小和PDI,同时增加了黄素的封装效率 (EE).
- 含黄素的NP表现出极好的体稳定性 (泽塔电位<-20mV),良好的生物相容性和有效的自由基清除.
- 在体内研究证实了NP能够缓解硫酸诱导的肠炎的能力,显示了性结肠炎治疗的前景.
结论:
- 微流体生成的Z+S混合NP提供了一个稳定有效的库尔库输送平台.
- 这些NP增强了黄素的生物可用性,并显示出对肠炎和性结肠炎的显著治疗潜力.
- 开发的系统代表了功能性食品和治疗应用的有希望的战略.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
01:26Peptic Ulcer Disease IV: Management
60
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
60
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
366
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
366